CPRX - This Growth Stock's Jaw-Dropping Run-Up Is Smashing Tesla's
Tesla stock might've made investors rich over the last few years, gaining more than 599.9% since late 2019, but 2022 has been a rough year for the company, with its shares losing slightly more than half their value amid a punishing bear market. In contrast, a little-known biotech called Catalyst Pharmaceuticals (NASDAQ: CPRX) gained 303% in 2022, and there's reason to believe that there's still plenty of upside to come.
In fact, the company is ripe for a purchase, and there's reason to believe it might continue to smash Tesla's return in 2023 and beyond. Here's why.
Catalyst owns the license to sell a medicine named Firdapse, which treats Lambert-Eaton Myasthenic Syndrome (LEMS), a rare neurological illness that causes muscle weakness and difficulty in performing everyday functional movements like getting out of bed or walking up a flight of stairs without stumbling. Firdapse is the only medicine that's indicated specifically to treat LEMS, which makes it a first-line treatment by definition. And that means Catalyst has had the market for LEMS drugs largely to itself since Firdapse's launch in early 2019.
For further details see:
This Growth Stock's Jaw-Dropping Run-Up Is Smashing Tesla's